These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16831934)

  • 1. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
    Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
    Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.
    Colucci S; Brunetti G; Rizzi R; Zonno A; Mori G; Colaianni G; Del Prete D; Faccio R; Liso A; Capalbo S; Liso V; Zallone A; Grano M
    Blood; 2004 Dec; 104(12):3722-30. PubMed ID: 15308561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
    Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
    J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin is expressed in colon carcinoma cells.
    Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
    Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
    Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients.
    Brunetti G; Colucci S; Pignataro P; Coricciati M; Mori G; Cirulli N; Zallone A; Grassi FR; Grano M
    J Periodontol; 2005 Oct; 76(10):1675-80. PubMed ID: 16253089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
    Holen I; Croucher PI; Hamdy FC; Eaton CL
    Cancer Res; 2002 Mar; 62(6):1619-23. PubMed ID: 11912131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and functional activity of osteoprotegerin in human malignant gliomas.
    Naumann U; Wick W; Beschorner R; Meyermann R; Weller M
    Acta Neuropathol; 2004 Jan; 107(1):17-22. PubMed ID: 14504888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice.
    Sedger LM; Glaccum MB; Schuh JC; Kanaly ST; Williamson E; Kayagaki N; Yun T; Smolak P; Le T; Goodwin R; Gliniak B
    Eur J Immunol; 2002 Aug; 32(8):2246-54. PubMed ID: 12209637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.
    Zauli G; Secchiero P
    Cytokine Growth Factor Rev; 2006 Aug; 17(4):245-57. PubMed ID: 16750931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of osteoprotegerin (OPG) in cancer.
    Holen I; Shipman CM
    Clin Sci (Lond); 2006 Mar; 110(3):279-91. PubMed ID: 16464170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.